Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
ViewAttendees 5

Z4. COVID-19 Treatment

Session: COVID-19 Treatment & Diagnostics

38 - Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality

On Demand
Participants should be aware of the following financial/non-financial relationships:
Essy Mozaffari, PharmD, MPH, MBA: Gilead Sciences (Employee, Shareholder)
Aastha Chandak, PhD: Gilead Sciences (Other Financial or Material Support, Employee of Certara (contracted by Gilead to conduct this study))
Zhiji Zhang, MS: Gilead Sciences (Other Financial or Material Support, Employee of Certara (contracted by Gilead to conduct this study))
Shuting Liang, MPH: Gilead Sciences (Employee)
Mark Thrun, MD: Gilead Sciences (Employee, Shareholder)
Robert L. Gottlieb, MD: Eli Lilly (Scientific Research Study Investigator, Advisor or Review Panel member)Gilead Sciences (Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Gift in kind to Baylor Scott and White Research Institute for NCT03383419)GSK (Advisor or Review Panel member)Johnson and Johnson (Scientific Research Study Investigator)Kinevant (Scientific Research Study Investigator)Roche/Genentech (Scientific Research Study Investigator)
Daniel R. Kuritzkes, MD: Abpro (Consultant)Atea (Consultant, Scientific Research Study Investigator)Decoy (Consultant)Gilead Sciences (Consultant, Grant/Research Support)GSK (Consultant)Janssen (Consultant)Merck (Consultant, Grant/Research Support)Novartis (Scientific Research Study Investigator)Rigel (Consultant)ViiV (Consultant, Grant/Research Support)
Paul Sax, MD: Gilead Sciences (Consultant, Grant/Research Support)Janssen (Consultant)Merck (Consultant, Research Grant or Support)ViiV (Consultant, Research Grant or Support)
David Alain Wohl, MD: Gilead Sciences (Individual(s) Involved: Self): Advisor or Review Panel member, Consultant, Research Grant or Support, Scientific Research Study Investigator; Janssen (Individual(s) Involved: Self): Advisor or Review Panel member; Merck (Individual(s) Involved: Self): Advisor or Review Panel member, Research Grant or Support; ViiV (Individual(s) Involved: Self): Advisor or Review Panel member, Research Grant or Support
Roman Casciano, M.Eng: Gilead Sciences (Other Financial or Material Support, Employee of Certara (contracted by Gilead to conduct this study))
Paul Hodgkins, PhD, MSc: Gilead Sciences (Employee, Shareholder)
Richard Haubrich, MD: Gilead Sciences (Employee, Shareholder)

    Presenting Author(s)

  • Essy Mozaffari, PharmD, MPH, MBA

    Senior Director
    Gilead Sciences
    Foster City, California, United States

    Gilead Sciences (Employee, Shareholder)

    Slides Slides and Audio

    • Co-Author(s)

  • AC

    Aastha Chandak, PhD

    Senior Manager, Head US Statistics
    Certara
    New York, New York, United States

    Gilead Sciences (Other Financial or Material Support, Employee of Certara (contracted by Gilead to conduct this study))

  • ZZ

    Zhiji Zhang, MS

    Statistical Analyst
    Certara
    Jersey City, New Jersey, United States

    Gilead Sciences (Other Financial or Material Support, Employee of Certara (contracted by Gilead to conduct this study))

  • SL

    Shuting Liang, MPH

    Senior Manager
    Gilead Sciences
    Foster City, California, United States

    Gilead Sciences (Employee)

  • MT

    Mark Thrun, MD

    Executive Director
    Gilead Sciences
    Foster City, California, United States

    Gilead Sciences (Employee, Shareholder)

  • RG

    Robert L. Gottlieb, MD

    Practicing Physician
    Baylor University Medical Center
    Dallas, Texas, United States

    Eli Lilly (Scientific Research Study Investigator, Advisor or Review Panel member)Gilead Sciences (Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Gift in kind to Baylor Scott and White Research Institute for NCT03383419)GSK (Advisor or Review Panel member)Johnson and Johnson (Scientific Research Study Investigator)Kinevant (Scientific Research Study Investigator)Roche/Genentech (Scientific Research Study Investigator)

  • DK

    Daniel R. Kuritzkes, MD

    Chief, Division of Infectious Diseases
    Brigham and Women's Hospital
    Cambridge, Massachusetts, United States

    Abpro (Consultant)Atea (Consultant, Scientific Research Study Investigator)Decoy (Consultant)Gilead Sciences (Consultant, Grant/Research Support)GSK (Consultant)Janssen (Consultant)Merck (Consultant, Grant/Research Support)Novartis (Scientific Research Study Investigator)Rigel (Consultant)ViiV (Consultant, Grant/Research Support)

  • Paul Sax, MD

    Clinical Director
    Brigham and Women's Hospital
    Boston, MA, United States

    Gilead Sciences (Consultant, Grant/Research Support)Janssen (Consultant)Merck (Consultant, Research Grant or Support)ViiV (Consultant, Research Grant or Support)

  • David Alain Wohl, MD

    Professor of Medicine
    UNC School of Medicine
    Chapel Hill, NC, United States

    Gilead Sciences (Consultant, Grant/Research Support, Advisor or Review Panel member)Janssen (Consultant, Advisor or Review Panel member)Merck (Consultant, Grant/Research Support, Advisor or Review Panel member)ViiV (Consultant, Grant/Research Support, Advisor or Review Panel member)

  • RC

    Roman Casciano, M.Eng

    General Manager
    Certara
    New York, New York, United States

    Gilead Sciences (Other Financial or Material Support, Employee of Certara (contracted by Gilead to conduct this study))

  • PH

    Paul Hodgkins, PhD, MSc

    Executive Director
    Gilead Sciences
    Foster City, California, United States

    Gilead Sciences (Employee, Shareholder)

  • RH

    Richard Haubrich, MD

    Vice President
    Gilead Sciences
    Foster City, California, United States

    Gilead Sciences (Employee, Shareholder)